Investors with a keen eye on the biotechnology sector might find Replimune Group, Inc. (NASDAQ: REPL) an intriguing opportunity. With its focus on pioneering oncolytic immunotherapies for cancer, Replimune stands out in the healthcare landscape. Despite the inherent risks associated with clinical-stage biotech firms, Replimune’s promising portfolio and substantial market potential merit a closer look.

**Company and Market Overview**

Replimune, headquartered in Woburn, Massachusetts, is at the forefront of developing oncolytic immunotherapies, which are designed to activate the immune system to combat cancer. Their flagship product, RP1, alongside other innovative candidates like RP2 and RP3, represents a promising approach to…